Associations of menopausal age with virological outcomes and engagement in care among women living with HIV in the UK

References

• Brown A, Rawson S, Kelly C, et al. Women and HIV in the UK: October 2019. London: Public Health England; 2019.
   Google Scholar
• Mahy M, Autenrieth CS, Stanecki K, et al. Increasing trends in HIV prevalence among people aged 50 years and older. AIDS 2014;28:S453–S459.
   Web of Science ®Google Scholar
• Solomon D, Sabin CA, Mallon PWG, et al. Cardiovascular disease in women living with HIV: a narrative review. Maturitas 2018;108:58–70.
   PubMed Web of Science ®Google Scholar
• Duff PK, Money DM, Ogilvie GS, et al. Severe menopausal symptoms associated with reduced adherence to antiretroviral therapy among perimenopausal and menopausal women living with HIV in Metro Vancouver. Menopause 2018;25:531–537.
   PubMed Web of Science ®Google Scholar
• Cutimanco-Pacheco V, Arriola-Montenegro J, Mezones-Holguin E, et al. Menopausal symptoms are associated with non-adherence to highly active antiretroviral therapy in human immunodeficiency virus-infected middle-aged women. Climacteric 2020;23(3):229–228.
   PubMed Web of Science ®Google Scholar
• Calvet GA, Velasque L, Luz PM, et al. Absence of effect of menopause status at initiation of first-line antiretroviral therapy on immunologic or virologic responses: a cohort study from Rio de Janeiro, Brazil. PLoS One 2014;9(2):e89299.
   Web of Science ®Google Scholar
• Solomon D, Sabin CA, Burns F, et al. The association between severe menopausal symptoms and engagement with HIV care and treatment in women living with HIV. AIDS Care 2020:1–8.
   Web of Science ®Google Scholar
• Apisarnthanarak A, Mundy LM. Long-term outcomes of HIV-infected patients with <95% rates of adherence to nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis. 2010;51:115–117.
   PubMed Web of Science ®Google Scholar
• Bastard M, Pinoges L, Balkan S, et al. Timeliness of clinic attendance is a good predictor of virological response and resistance to antiretroviral drugs in HIV-infected patients. PloS One 2012;7(11):e49091.
   PubMed Web of Science ®Google Scholar
• Committee UCHCS. The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med. 2004;5:115–124.
   Web of Science ®Google Scholar
• Howarth AR, Burns FM, Apea V, et al. Development and application of a new measure of engagement in out-patient HIV care. HIV Med. 2017;18(4):267–274.
   Web of Science ®Google Scholar
• Howarth A, Apea V, Michie S, et al. REACH: a mixed-methods study to investigate the measurement, prediction and improvement of retention and engagement in outpatient HIV care. Health Serv Deliv Res. 2017;5(13):1–160.
   Google Scholar
• Olatosi BA, Probst JC, Stoskopf CH, et al. Patterns of engagement in care by HIV-infected adults: South Carolina, 2004-2006. AIDS 2009;23(6):725–730.
   PubMed Web of Science ®Google Scholar
• Kiplagat J, Mwangi A, Keter A, et al. Retention in care among older adults living with HIV in western Kenya: a retrospective observational cohort study. Plos One 2018;13(3):e0194047.
   PubMed Web of Science ®Google Scholar
• Sabin CA, Howarth A, Jose S, et al. Association between engagement in-care and mortality in HIV-positive persons. AIDS 2017;31(5):653–660.
   PubMed Web of Science ®Google Scholar
• Alejos B, Suarez I, Sanz N, et al., Does menopause affect treatment response in HIV-infected women? A multicenter cohort in Spain. InL 17th European AIDS Conference, Basel; 2019.
   Google Scholar
• Greenbaum AH, Wilson LE, Keruly JC, et al. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS 2008;22:2331–2339.
   PubMed Web of Science ®Google Scholar
• COHERE Group. Response to combination antiretroviral therapy: variation by age. AIDS 2008;22:1463–1473.
   Google Scholar
• Ghidei L, Simone MJ, Salow MJ, et al. Aging, antiretrovirals, and adherence: a meta analysis of adherence among older HIV-infected individuals. Drugs Aging 2013;30(10):809–819.
   PubMed Web of Science ®Google Scholar
• Kowalska JD, Kubicka J, Siwak E, et al. Factors associated with the first antiretroviral therapy modification in older HIV-1 positive patients. AIDS Res Ther. 2016;13(1):2.
   Google Scholar
• Zhang Q, Yu X, Wu T, et al. Immunological and virological responses in older HIV-infected adults receiving antiretroviral therapy: an evidence-based meta-analysis. J Acquir Immune Defic Syndr. 2020;83(4):323–333.
   Web of Science ®Google Scholar
• Orlando G, Meraviglia P, Cordier L, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med. 2006;7(8):549–557.
   PubMed Web of Science ®Google Scholar
• Althoff KN, Justice AC, Gange SJ, et al. Virologic and immunologic response to HAART, by age and regimen class. AIDS 2010;24:2469–2479.
   Web of Science ®Google Scholar
• Szadkowski L, Tseng A, Walmsley SL, et al. Short communication: effects of age on virologic suppression and CD4 cell response in HIV-positive patients initiating combination antiretroviral therapy. AIDS Res Hum Retroviruses. 2012;28(12):1579–1583.
   Web of Science ®Google Scholar
• Dawood H, Hassan-Moosa R, Zuma N-Y, et al. Mortality and treatment response amongst HIV-infected patients 50 years and older accessing antiretroviral services in South Africa. BMC Infect Dis. 2018;18(1):168.
   PubMedGoogle Scholar
• Carriquiry G, Giganti MJ, Castilho JL, et al. Virologic failure and mortality in older ART initiators in a multisite Latin American and Caribbean Cohort. J Intern AIDS Soc. 2018;21(3):e25088.
   Web of Science ®Google Scholar
• Barber TJ, Geretti AM, Anderson J, et al. Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antivir Ther. 2011;16(6):805–814.
   Web of Science ®Google Scholar
• Patterson K, Napravnik S, Eron J, et al. Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy. HIV Med. 2007;8(6):406–410.
   PubMed Web of Science ®Google Scholar
• Raboud J, Blitz S, Walmsley S, et al. Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy. HIV Clin Trials.2010;11(6):340–350.
   PubMed Web of Science ®Google Scholar
• The National Institute of Health and Care Excellence (NICE) Guideline. Menopause: Diagnosis and Management.
   Google Scholar
• Tseng A, Szadkowski L, Walmsley S, et al. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother. 2013;47(11):1429–1439.
   PubMed Web of Science ®Google Scholar
• Edelman EJ, Gordon KS, Glover J, et al. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging. 2013;30(8):613–628.
   PubMed Web of Science ®Google Scholar
• Sherr L, Molloy A, Macedo A, et al. Ageing and menopause considerations for women with HIV in the UK. J Virus Erad. 2016;2(4):215–218.
   PubMed Web of Science ®Google Scholar
• Loutfy M, Andany N, Kennedy VL, et al. Perspectives on menopause and women with HIV. Int J Women's Health. 2016;8:1–22.
   Web of Science ®Google Scholar
• Imai K, Sutton MY, Mdodo R, et al. HIV and menopause: a systematic review of the effects of HIV infection on age at menopause and the effects of menopause on response to antiretroviral therapy. Obstet Gynecol Int. 2013;2013:1–11.
   Google Scholar
• 36.British HIV Association. 2018 Standards of Care for People Living with HIV. London: BHIVA; 2018.
   Google Scholar